GMP-like CAR Vector Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

CAR Vectors

Lentiviral vectors and gamma retroviral vectors are currently the primary viral vectors used in CAR T cell therapy, with the former being widely adopted due to its broad applicability and higher safety profile. Lentiviral vectors can effectively integrate genes into the genomes of resting cells, making them suitable for various cell types, including T cells. The advantages of lentiviral vectors include their larger gene capacity and lower immunogenicity. Gamma retroviral vectors are primarily used to transduce dividing cells, and thus they also have applications in CAR T cell therapy. While they can be effective in certain situations, their use is limited compared to lentiviral vectors because they cannot infect resting cells.

Fig.1 An overview of the lentiviral vector systems.Fig. 1 The three generations of lentiviral plasmid systems.1

By distributing viral genes across multiple plasmids, the risk of generating replication-competent lentiviruses (RCLs) is reduced, which is crucial for clinical applications. It showcases the evolution of lentiviral vector technology, highlighting improvements from the first to the third generation, which reflect the efforts made by scientists to enhance safety and efficiency.

GMP-like CAR Vector

A GMP-like production process emphasizes strict control over the production environment, equipment, and raw materials to ensure the quality of the final product. By manufacturing products under GMP-like conditions, the risk of potential contamination is reduced, ensuring that the products are free from harmful substances, thereby enhancing safety. The significance of GMP-like level production lies in ensuring that the production process is safe, effective, and reproducible.

GMP-like CAR vectors are designed for preclinical studies. They serve as an intermediary between research-grade vectors and full GMP-grade vectors. GMP-like vectors are primarily used in preclinical studies, which may include drug discovery and testing.

Key Features of GMP-like CAR Vector

  • The turnaround time for GMP-like viral vector plasmid production is several months. It ranges from 4 to 5 months for lentivirus.
  • Quality System: GMP-like vectors are produced under an ISO9001 quality system while adopting key features of GMP systems. This ensures a level of quality control that is suitable for preclinical applications.
  • Quality Control tests: concentration, sequencing, endotoxin levels, etc.

GMP-like vectors from Creative Biolabs are tailored for preclinical applications, providing a balance between research-grade and full GMP-grade vectors, with a focus on quality and regulatory compliance. Scaling production to a GMP-like level can be viewed as a simulated version of small-scale GMP manufacturing. This method provides a more economical and time-saving option compared to full-scale GMP production.

Creative Biolabs offers a variety of GMP-like products. For more details, welcome to contact us. For other GMP Products, please click on the categories below:

Reference

  1. Labbé, R. P., Vessillier, S., & Rafiq, Q. A. "Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives." Viruses, 13.8 (2020): 1528. Distributed under Open Access license CC BY 4.0, without modification.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.